Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

disease progression

- PMLiVE

Measure your omnichannel maturity with our new tool

Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness.

Avalere Health

- PMLiVE

European Commission approves potential new treatment for Pompe disease

Nexviadyme is the first and only newly approved medicine for Pompe disease in Europe in over 15 years

- PMLiVE

The digital-first launch: the key to connected stakeholder experiences?

During the COVID-19 pandemic, a new digital-first launch model emerged as a gamechanger for driving better customer experiences. Here, Senior Consultant Srividya Sekar; Senior Associate Consultant, Erin Johnstone; and Associate...

Avalere Health

- PMLiVE

EU governments pressure manufacturers to renegotiate contracts for COVID-19 vaccines

EU officials have warned that millions of vaccine doses could be wasted due to over-supply

- PMLiVE

EC approves Roche’s Tecentriq for early-stage lung cancer

Tecentriq has now become the first cancer immunotherapy approved in Europe for the treatment of certain types of early-stage NSCLC

- PMLiVE

Roche’s Polivy receives EC approval for lymphoma therapy

The combination therapy is for patients with previously untreated diffuse large B-cell lymphoma

- PMLiVE

EC approves Novartis’ Kymriah for advanced blood cancer

Kymriah is the first CAR-T cell therapy of its kind approved in the EU for follicular lymphoma

- PMLiVE

Sanofi’s asthma treatment approved by European Commission

Dupixent is suitable for 6- to 11-year-old children who have severe asthma and type 2 inflammation

- PMLiVE

Merck KGaA to make $3m payout to patients after drug formulation complaints

La Cour de Cassation has ordered the company to make the payment to more than 3,000 patients to settle the reformulation dispute

- PMLiVE

Merck KGaA’s Glucophage approved in Europe as first oral diabetic medication for use during pregnancy

The oral drug offers comparable maternal blood sugar control to insulin, which needs to be injected

EU flag

Global Blood Therapeutics’ treatment for patients with sickle cell disease approved in Europe

The once-daily oral drug is the first medicine approved in Europe to treat the condition in adults and paediatric patients 12 years and older

Protecting Ownership of Technological & Pharmaceutical Innovation

Joshua Goldberg, Co-Managing Partner at Nath, Goldberg & Meyer, discusses key intellectual property issues and pitfalls in the digital health space, the importance of international patent protection, and why it’s...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links